Spero Therapeutics is a privately owned clinical-stage biopharmaceutical company headquartered in Cambridge Massachusetts. The company focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections.
Spero's lead product candidate is SPR994, which is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections, especially complicated urinary tract infections (cUTI). The treatment is derived from tebipenem, an antibiotic produced by Meiji Seika Pharma in Japan, which is used to treat common pediatric infections including pneumonia, otitis media, and sinusitis.
Spero is also pursuing a couple of product candidates through its IV Potentiator Platform. SPR741 is an IV product that when combined with an antibiotic, has demonstrated the ability to expand the spectrum and potency of the co-administered antibiotic against Gram-negative bacteria.
It has completed Phase 1A and 1B clinical trials highlighting its tolerability and pharmacokinetic profile. SPR206 is an IV direct-acting antibiotic that has shown activity against Acinetobacter baumanii and Pseudomonas aeruginosa in preclinical studies. It has completed non-clinical, IND enabling studies supporting its advancement as a clinical candidate to treat MDR and extensively drug-resistant (XDR) bacterial strains.
Spero has another product candidate, SPR720, in very early stages. It is an oral therapy designed for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections. In November 2018, the company announced positive results from its IND-enabling studies and intends to initiate Phase 1 clinical trials in early 2019.
Spero Therapeutics raises a $51,700,000 series C round from RA Capital Management, Rock Springs Capital and GV.
Spero Therapeutics was founded.
President & CEO
Head of Regulatory Affairs
Chief Medical Officer
Ian A. Critchley
Head of Clinical Microbiology
Head of People Strategy and Culture
Executive Director of Strategic Alliances
Executive Director - Early Drug Discovery
Senior VP of Finance and Operations
Head of Clinical Operations
Chief Scientific Officer
Senior VP of Development
VP of Research
Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial
Spero Therapeutics, Inc.
Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720
Spero Therapeutics, Inc.
Documentaries, videos and podcasts
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.